Compile Data Set for Download or QSAR
Report error Found 49 Enz. Inhib. hit(s) with all data for entry = 11646
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636570(US20230365583, Compound 38)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636559(US20230365583, Compound 26)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636560(US20230365583, Compound 27)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636561(US20230365583, Compound 28)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636562(US20230365583, Compound 29)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM481897(US10913753, Compound I-1 | US20230365583, Compound...)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636564(US20230365583, Compound 31)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636565(US20230365583, Compound 32)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636566(US20230365583, Compound 33)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636567(US20230365583, Compound 35)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636568(US20230365583, Compound 36)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636569(US20230365583, Compound 37)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636558(US20230365583, Compound 25)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636571(US20230365583, Compound 39)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636572(US20230365583, Compound 40)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636573(US20230365583, Compound 41)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636574(US20230365583, Compound 42)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636575(US20230365583, Compound 43)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636577(US20230365583, Compound 45)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636578(US20230365583, Compound 46)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636579(US20230365583, Compound 47)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636580(US20230365583, Compound 48)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636581(US20230365583, Compound 49)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636582(US20230365583, Compound 50)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636556(US20230365583, Compound 24)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636533(US20230365583, Compound 2)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636540(US20230365583, Compound 9)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636541(US20230365583, Compound 10)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636543(US20230365583, Compound 12)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636548(US20230365583, Compound 17)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636549(US20230365583, Compound 18)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM482105(US10913753, Compound I-172 | US20230365583, Compou...)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636532(US20230365583, Compound 1)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636550(US20230365583, Compound 19)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM481946(US10913753, Compound I-13 | US20230365583, Compoun...)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636553(US20230365583, Compound 21)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636551(US20230365583, Compound 20)
Affinity DataIC50: 1.00E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636544(US20230365583, Compound 13)
Affinity DataIC50: 5.50E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636546(US20230365583, Compound 15)
Affinity DataIC50: 5.50E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636547(US20230365583, Compound 16)
Affinity DataIC50: 5.50E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636539(US20230365583, Compound 8)
Affinity DataIC50: 5.50E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636576(US20230365583, Compound 44)
Affinity DataIC50: 5.50E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636537(US20230365583, Compound 6)
Affinity DataIC50: 5.50E+3nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636545(US20230365583, Compound 14)
Affinity DataIC50: 5.50E+4nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636542(US20230365583, Compound 11)
Affinity DataIC50: 5.50E+4nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636538(US20230365583, Compound 7)
Affinity DataIC50: 5.50E+4nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636535(US20230365583, Compound 4)
Affinity DataIC50: 5.50E+4nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636534(US20230365583, Compound 3)
Affinity DataIC50: 5.50E+4nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM636536(US20230365583, Compound 5)
Affinity DataIC50: 1.00E+5nMAssay Description:USP28 (at 1 nM) was pre-incubated with different concentrations of inhibitors or DMSO as a control in 50 mM Tris pH 8, 50 mM NaCl, 0.002% Tween-20, 5...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2024
Entry Details
Go to US Patent